A method for quantification of the concentration of one or more cannabinoid compounds in a liquid sample is provided. The method involves contacting the liquid sample with at least one cannabinoid-sensitive visualization reagent, allowing the at least one cannabinoid-sensitive visualization reagent to develop for a defined amount of time; and comparing the resulting color change of the at least one cannabinoid-sensitive visualization reagent to a calibrated quantification reference chart.

Materials and methods for testing unknown substances for the presence of an opioid are described.

Disclosed herein are methods of detecting ascorbic acid in a urine sample from a subject, including contacting at least a portion of the urine sample with a test strip including a reagent pad and detecting whether ascorbic acid is present in the urine sample by measuring an intensity of color on the reagent pad, wherein a reduction in the intensity of color on the reagent pad indicates the presence of ascorbic acid.

The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised.

A method for quantification of the concentration of one or more cannabinoid compounds in a liquid sample is provided. The method involves contacting the liquid sample with at least one cannabinoid-sensitive visualization reagent, allowing the at least one cannabinoid-sensitive visualization reagent to develop for a defined amount of time; and comparing the resulting color change of the at least one cannabinoid-sensitive visualization reagent to a calibrated quantification reference chart.

The invention provides a system of heavy metal sequestration by bacteria. The bacteria expresses the ppk, mt, and/or β-galactosidase (lacZ) genes and can tolerate at least 25 μM mercury, 1,000 μM zinc, 250 μM cadmium, and 3,000 μM Pb. The system allows for facile determination of the presence of heavy metal contaminants in a liquid and the facile collection of the bacteria that has sequestered large amounts of heavy metal. Further provided is a system of gene expression in bacteria that comprises phage and plastid gene expression elements and delivers a particularly high level of protein expression and heavy metal resistance.

Provided is a fluidic device, including: a porous flow path member; an absorbent member contacting the flow path member and configured to absorb a liquid; and a barrier member covering at least a portion of the absorbent member, wherein the absorbent member contains a liquid-absorbent polymer that absorbs the liquid, and a lyophilic polymer having lyophilicity to the liquid.

A multiplexed vertical flow serodiagnostic testing device for diseases such as Lyme disease includes one or more multi-piece cassettes that include vertical stacks of functionalized porous layers therein. A bottom piece of the cassette includes a sensing membrane with a plurality of spatially multiplexed immunoreaction spots or locations. Top pieces are used to deliver sample and/or buffer solutions along with antibody-conjugated nanoparticles for binding with the immunoreaction spots or locations. A colorimetric signal is generated by the nanoparticles captured on the sensing membrane containing disease-specific antigens. The sensing membrane is imaged by a cost-effective portable reader device. The images captured by the reader device are subject to image processing and analysis to generate positive (+) or negative (−) indication for the sample. A concentration of one or more biomarkers may also be generated. The testing device is rapid, simple, inexpensive, and allows for simultaneous measurement of multiple antibodies and/or antigens making it an ideal point-of-care platform for disease diagnosis.

Treatment of neurodegenerative diseases with copper nanoclusters (CuNCs), where the neurodegenerative diseases include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), and glaucoma.

A method of testing for an analyte in an individual comprises providing colour information obtained from a digital image of a coloured reagent on an analyte test strip, the coloured reagent having been generated in accordance with analyte in a test sample, converting the colour information from the image into an analyte level, recording the analyte level in association with user-specific information (e.g. a QR code), repeating the above steps to obtain two or more records of analyte levels for the same user at different times and using the records to monitor personal health or to predict the likely development of a disease or condition or to diagnose a disease or condition or to monitor a treatment regime associated with variation in analyte levels in saliva.